Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HLX15 vs Daratumumab in Healthy Chinese Males
NCT05679258Phase 1Completed
- Sponsor
- Henlius
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX15-IV in multiple myeloma (MM) (3 arms), sponsored by Henlius. Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity at Day 91. Started Jan 2023; status: completed.
02
Drugs
HLX15-IV
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05679258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679258.